Related references
Note: Only part of the references are listed.A Comprehensive Tyrosine Phosphoproteomic Analysis Reveals Novel Components of the Platelet CLEC-2 Signaling Cascade
Irene Izquierdo et al.
THROMBOSIS AND HAEMOSTASIS (2020)
β4GALT1 controls β1 integrin function to govern thrombopoiesis and hematopoietic stem cell homeostasis
Silvia Giannini et al.
NATURE COMMUNICATIONS (2020)
Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs
Ozgun Babur et al.
BLOOD (2020)
Platelet Dysfunction and Thrombosis in JAK2V617F-Mutated Primary Myelofibrotic Mice
Shinobu Matsuura et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
C-Cbl regulates c-MPL receptor trafficking and its internalization
Melanie Maerklin et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Dynamin 2 is required for GPVI signaling and platelet hemostatic function in mice
Nathan Eaton et al.
HAEMATOLOGICA (2020)
GPVI signaling is compromised in newly formed platelets after acute thrombocytopenia in mice
Shuchi Gupta et al.
BLOOD (2018)
von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice
P. M. Jacobi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays
Tesse C. Leunissen et al.
PLATELETS (2017)
Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice
Viola Lorenz et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice
Markus Bender et al.
BLOOD (2015)
JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation
Rodolphe Besancenot et al.
BLOOD (2014)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi et al.
BLOOD (2014)
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
Lamia Lamrani et al.
BLOOD (2014)
Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis
Sara C. Meyer et al.
BLOOD (2014)
JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms
S. Leah Etheridge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation
Ashley P. Ng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Role of a Janus kinase 2-dependent signaling pathway in platelet activation
Wan-Jung Lu et al.
THROMBOSIS RESEARCH (2014)
Dysfunction of the PI3 kinase/Rap1/integrin αIIbβ3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia
Samantha F. Moore et al.
BLOOD (2013)
JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia
Catherine M. Hobbs et al.
BLOOD (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
Ab Initio Modeling and Experimental Assessment of Janus Kinase 2 (JAK2) Kinase-Pseudokinase Complex Structure
Xiaobo Wan et al.
PLOS COMPUTATIONAL BIOLOGY (2013)
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes
Christian Pecquet et al.
BLOOD (2012)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices
Ayalew Tefferi
LEUKEMIA & LYMPHOMA (2010)
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
Federico Lussana et al.
THROMBOSIS RESEARCH (2009)
Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
Akyalew Tefferi et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo
Ralph Tiedt et al.
BLOOD (2007)
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
Guido Finazzi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
GPVI and integrin αIIβ3 signaling in platelets
SP Watson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Janus kinases affect thrombopoietin receptor cell surface localization and stability
Y Royer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Importance of platelet phospholipase Cγ2 signaling in arterial thrombosis as a function of lesion severity
C Nonne et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
MA Elliott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice
A Krempler et al.
GENESIS (2004)
Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice
KU Wagner et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Platelet-collagen interaction: is GPVI the central receptor?
B Nieswandt et al.
BLOOD (2003)
Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions
SY Goto et al.
CIRCULATION (2002)
Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP
TM Quinton et al.
BLOOD (2002)
Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin
BT Atkinson et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Share Paper
